Skip to content

Gilead Says FDA Verdict on Outpatient Remdesivir Likely Soon

  • Drug could fill a void as other treatment supplies remain thin
  • Drugmaker also looking at future combination Covid therapies
Vials of Gilead's Remdesivir.
Vials of Gilead's Remdesivir.

Photographer: Ulrich Perrey/AFP/Getty Images

Updated on

U.S. regulators may decide within a week or two whether to approve a shorter course of Gilead Sciences Inc.’s Covid-19 drug remdesivir that could be used for patients outside the hospital, Chief Executive Officer Daniel O’Day said in an interview.

A five-day course of the infused drug is already a mainstay for hospitalized Covid patients. Gilead has applied for U.S. clearance of a three-day course that could be used in the outpatient setting, after a big trial last year showed it could sharply reduce hospitalizations in at-risk patients.